Table 1.
Summary of axon targeting of 21 ORN classes in ey-FLP- or hs-FLP-induced control, smo, ihog or ptc Mutant clones
| ORN Class |
Glomerular target(s) |
ey-FLP WT(40A) |
ey-FLP smo3 |
ey-FLP ihog |
hs-FLP WT(40A) |
hs-FLP smo3 |
hs-FLP ihog |
hs-FLP WT(42D) |
hs-FLP ptcIIW |
|---|---|---|---|---|---|---|---|---|---|
| Or10a | DL1 | 8% (24) | 8% (26) | 6% (16) | not determined | (n.d.) | n.d. | 17% (24) | 83% (24) |
| Or22a | DM2 | 0% (20) | 4% (24) | 0% (23) | n.d. | n.d. | n.d. | 7% (29) | 18% (34) |
| Or23a | DA3 (DC3) | 5% (21) | 0% (28) | 7% (15) | 0% (9) | 0% (14) | n.d. | 6% (34) | 25% (24) |
| Or47b | VA1l/m | 0% (21) | 0% (20) | 0% (22) | 0% (12) | 0% (8) | n.d. | 4% (25) | 33% (33) |
| Or67b | VA3 | 14% (21) | 5% (22) | 5% (22) | n.d. | n.d. | n.d. | 3% (34) | 28% (39) |
| Gr21a | V | 9% (22) | 0% (25) | 0% (23) | n.d. | n.d. | n.d. | 6% (33) | 26% (34) |
| Or42a | VM7 (V, VL2p) | 4% (24) | 7% (28) | 0% (20) | 13% (16) | 4% (23) | n.d. | 10% (20) | 6% (18) |
| Or47a | DM3 | 5% (21) | 3% (29) | 0% (29) | 14% (14) | 0% (12) | n.d. | 0% (20) | 5% (20) |
| Or71a | VC2 | 6% (17) | n.i (39) | 0% (22) | 8% (12) | 0% (26) | n.d. | 7% (28) | 6% (31) |
| Or88a | VA1d | 0% (20) | 0% (20) | 10% (20) | n.d. | n.d. | n.d. | 0% (21) | 7% (14) |
| Or92a | VA2 | 0% (20) | 5% (20) | 0% (22) | n.d. | n.d. | n.d. | 0% (20) | 0% (15) |
| Or9a | VM3 | 15% (26) | 26% (19) | 38% (8) | n.d. | n.d. | n.d. | n.d. | n.d. |
| Or13a | DC2 | 4% (28) | 28% (25) | 17% (29) | 4% (24) | 12% (26) | 26% (34) | n.d. | n.d. |
| Or43a | DA4l | 9% (22) | 72% (25) | 22% (23) | 14% (21) | 25% (40) | 23%(30) | 6% (18) | 8% (24) |
| Or43b | VM2 (DM5) | 0% (9) | 13% (15) | 8% (25) | 0% (19) | 17% (30) | 5% (21) | 6% (36) | 0% (37) |
| Or46a | VA7l | 10% (20) | n.i. (24) | 27% (22) | 0% (9) | 25% (44) | 23% (35) | 12% (17) | 10% (10) |
| Or49b | VA5 | 8% (13) | 19% (36) | 13% (30) | 3% (29) | 4% (26) | 5% (21) | 0% (32) | 4% (26) |
| Or56a | DA2 | 10% (40) | 35% (40) | 19% (21) | 15% (20) | 40% (20) | 24%(50) | 5% (21) | 4% (26) |
| Or59c | 1(VM7) | 13% (16) | 55% (22) | 83% (24) | 8% (12) | 32% (38) | 45% (20) | 3% (29) | 8% (12) |
| Or83c | DC3 (VA6) | 5% (21) | 38% (21) | 20% (10) | 0% (15) | 18% (28) | 4% (23) | 8% (26) | 0% (19) |
| Or85e | VC1 | 0% (20) | 50% (20) | 50% (26) | 0% (10) | 22% (23) | 14% (29) | 9% (22) | 14% (22) |
Percentages represent fraction of brains with targeting defects over total number of brains (in parentheses) that show Or-Gal4-driven GFP-positive axons. In the case of ey-FLP clones for Or71a and Or46a, none of the brains were innervated by GFP-positive axons (n.i.). The spaced line in the middle divides the ORN classes whose axon targeting do not depend on Smo (above) and those that do (below). Parentheses in the “glomerular target(s)” column indicate the identity of secondary glomeruli targeted by ORNs with ectopic Gal4-expression of particular Or-Gal4 drivers even in controls. These were not counted as phenotypes. All targeting defects were scored blindly to the genotypes. Full genotypes are described in Table S1 and Table S2.